Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03420950 · ClinicalTrials.gov registry record · NA
Drug Order for Rapid Sequence Intubation
A NA study, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 335
- Enrollment target
NCT03420950: Completed NA study, sponsored by Hennepin Healthcare Research Institute.
NCT03420950 is a NA study that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 335 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03420950, a NA study, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 335 participants
- Enrollment target
Study Summary
This is a randomized, blinded trial comparing the order of drug administration for rapid sequence intubation in the Emergency Department.
Primary Outcome
The primary outcome will be time from complete administration of the first medication to successful first attempt intubation. This timing period will begin when the first RSI agent is completely administered and end when the laryngoscope blade is removed from the mouth. Attempts that are not successful on the first attempt will be excluded from the primary outcome measure because the time to intubation will be confounded by the failure; in these cases the altered duration will have more to do wi
Interventions
- OTHER Rapid sequence intubation: sedative first
- OTHER Rapid sequence intubation: paralytic first
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2021-09-29 |
| Phase | NA |
What the finished NCT03420950 record still lists
NCT03420950 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Rapid sequence intubation: sedative first is the first listed.
NCT03420950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03420950 about?
NCT03420950 is a clinical study titled "Drug Order for Rapid Sequence Intubation". This is a randomized, blinded trial comparing the order of drug administration for rapid sequence intubation in the Emergency Department.
What is the current status of trial NCT03420950?
This trial is currently completed. It is a NA study. The enrollment target is 335 participants. The study started on 2018-02-05. Estimated completion is 2021-09-29.
What interventions are being tested in trial NCT03420950?
The interventions under investigation include: Rapid sequence intubation: sedative first (OTHER), Rapid sequence intubation: paralytic first (OTHER).
Who is sponsoring clinical trial NCT03420950?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03420950's enrollment target sits among peer trials
335 305th of 2000 higher than 1,696 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI